Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
6.65
Oct 09 • 3:59 PM ET Dollar change+0.60 Percentage change(9.92%)
Aftermarket Close
6.65
Aftermarket • 4:15 PM ET Dollar change0.00 Percentage change(0.00%)
Oct 08, 7:05 AMNutriband files new U.S. patent application to extend AVERSA abuse-deterrent transdermal IP protection potentially to 2046
Index
-
Market Cap
80.83M
Enterprise Value
77.63M
Income
-6.96M
Sales
1.62M
Book/sh
0.44
Cash/sh
0.28
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
-
IPO
Nov 30, 2017
P/E
-
Forward P/E
-
PEG
-
P/S
49.90
P/B
15.18
P/C
23.64
P/FCF
-
EV/EBITDA
-
EV/Sales
47.92
Quick Ratio
4.02
Current Ratio
4.21
Debt/Eq
0.04
LT Debt/Eq
0.01
Option/Short
No / Yes
EPS (ttm)
-0.58
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
-69.50% -42.74%
Sales past 3/5Y
-0.69% 16.63%
EPS Y/Y TTM
79.94%
Sales Y/Y TTM
-37.25%
EPS Q/Q
96.59%
Sales Q/Q
-29.71%
Insider Own
56.81%
Insider Trans
0.00%
Inst Own
2.90%
Inst Trans
-2.67%
ROA
-84.55%
ROE
-100.75%
ROIC
-129.28%
Gross Margin
31.06%
Oper. Margin
-435.58%
Profit Margin
-430.43%
SMA20
-9.94%
SMA50
21.72%
SMA200
56.53%
Trades
Shs Outstand
12.16M
Shs Float
5.25M
52W High
9.19 -27.60%
52W Low
2.80 137.50%
Volatility
9.54% 12.65%
ATR (14)
0.79
RSI (14)
49.72
Beta
2.14
Rel Volume
0.73
Avg Volume
61.91K
Volume
45,134
Perf Week
-8.65%
Perf Month
9.38%
Perf Quarter
126.19%
Perf Half Y
70.51%
Perf YTD
46.48%
Perf Year
-15.93%
Perf 3Y
189.13%
Perf 5Y
15.80%
Perf 10Y
-
Prev Close
6.05
Price
6.65
Change %
9.92%
Date Action Analyst Rating Change Price Target Change
Jan-22-25Initiated Noble Capital Markets Outperform $13
Oct-08-26 07:00AM
Oct-01-26 04:05PM
Sep-29-26 09:25AM
Sep-25-26 08:00AM
Sep-22-26 08:00AM
09:20AM Loading…
Sep-09-26 09:20AM
Sep-08-26 09:00AM
Aug-13-26 07:00AM
May-15-26 07:00AM
Apr-22-26 07:00AM
Mar-30-26 04:05PM
Mar-18-26 07:00AM
Feb-17-26 07:28AM
Jan-30-26 07:00AM
Jan-01-26 07:10AM
07:00AM Loading…
Dec-31-25 07:00AM
Dec-29-25 09:00AM
Dec-18-25 08:00AM
07:00AM
Nov-24-25 07:00AM
Nov-20-25 08:10AM
Nov-13-25 05:15PM
Nov-12-25 05:40PM
Nov-11-25 05:10PM
Nov-10-25 08:25AM
Oct-28-25 11:05AM
07:00AM
Oct-27-25 07:00AM
Oct-10-25 07:00AM
Oct-08-25 08:30AM
06:30AM Loading…
06:30AM
Sep-25-25 08:00AM
Sep-24-25 04:05PM
Sep-10-25 09:15AM
Sep-09-25 06:45PM
Sep-03-25 04:01PM
Aug-27-25 06:20PM
Aug-18-25 09:00AM
Aug-14-25 08:10AM
Aug-13-25 08:15AM
Aug-11-25 06:55PM
05:00AM
Aug-08-25 08:00AM
Aug-07-25 08:05AM
Jul-18-25 09:15AM
Jul-02-25 08:05AM
Jul-01-25 07:00AM
Jun-18-25 07:00AM
Jun-09-25 07:30AM
Jun-03-25 08:00AM
Jun-02-25 08:00AM
May-30-25 05:20PM
May-27-25 08:00AM
Apr-30-25 07:30AM
Apr-11-25 07:00AM
Apr-04-25 05:41PM
07:00AM
Feb-21-25 07:00AM
Feb-13-25 07:00AM
Feb-11-25 09:00AM
Feb-07-25 08:45AM
Dec-31-24 07:00AM
Dec-28-24 09:30AM
Dec-27-24 09:25AM
Dec-04-24 09:00AM
07:00AM
Nov-27-24 07:00AM
Oct-31-24 08:35AM
Oct-17-24 07:00AM
Oct-02-24 07:00AM
Sep-24-24 08:45AM
07:00AM
Sep-20-24 06:50AM
Sep-16-24 04:00PM
Sep-04-24 07:00AM
Jul-19-24 07:00AM
Jul-15-24 07:00AM
Jun-25-24 06:52AM
Jun-20-24 07:00AM
Jun-03-24 07:00AM
May-21-24 07:00AM
May-16-24 07:00AM
May-10-24 09:00AM
May-03-24 11:54AM
Apr-25-24 07:00AM
Apr-24-24 07:00AM
Apr-23-24 07:00AM
Apr-19-24 07:00AM
Apr-01-24 07:00AM
Mar-27-24 05:50AM
Mar-25-24 07:00AM
Mar-04-24 07:00AM
Jan-29-24 07:00AM
Jan-26-24 07:00AM
Jan-05-24 09:15AM
Dec-18-23 11:52AM
Nov-28-23 07:00AM
Nov-08-23 07:00AM
Oct-11-23 07:42AM
Sep-20-23 09:15AM
Nutriband, Inc. engages in the development of a portfolio of transdermal pharmaceutical products. It operates through the Pocono Pharmaceuticals and 4P Therapeutics segments. The Pocono Pharmaceuticals segment relates to a coated products manufacturing entity. The 4P Therapeutics segment performs contract research and development services. The company was founded by Gareth R. Sheridan and Serguei Melnik in 2012 and is headquartered in Orlando, FL.
FounderMr. Serguei Melnik
FounderMr. Gareth Sheridan
CFO & Chief Accounting OfficerMr. Gerald Goodman
COO & President of 4P TherapeuticsDr. Alan Smith Ph.D.
Chief Scientific OfficerDr. Jeffrey Patrick Pharm.D.